Projects In Knowledge - Women's Health

Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer—Practical Case-Based Discussions

Projects In Knowledge is pleased to present Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer—Program Series. Featuring the very latest state-of-the-science information about practical therapeutic approaches for clinicians interested in improving outcomes in their patients with ovarian cancer – this free online program series offers CME, CE, and CPE credit. Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer—Program Series is building a community of experts to help you provide your patients with the best treatment outcome possible....more

B. Monk, MD, FACOG, FACS

The Advanced Certificate Program in Breast Cancer Management

Projects In Knowledge is pleased to present The Advanced Certificate Program: Breast Cancer Management.

Featuring the very latest state-of-the-science information about breast cancer diagnosis, breast cancer treatment, and breast cancer disease management, this free online curriculum offers CME, CE, and CPE credit to oncologists and other clinicians who care for patients with breast cancer.

The curriculum courses are updated continuously throughout the year.

The Advanced Certificate Program: Breast Cancer Management is building a community of experts to help you provide your patients with the best treatment outcome possible....more

H. Burstein, MD, PhD

Women's Cancers Edition

More than 250,000 women will be diagnosed with breast, ovarian, cervical, or endometrial/uterine cancer this year. In each of the six chapters, an oncology expert will focus on one cancer type or stage, elucidating the current standard of care, as well as highlighting what's on the horizon with therapies in development.

Please join the expert faculty for each chapter of this online and interactive "living" textbook....more

R. Coleman, MD

M. Fornier, MD

T. Herzog, MD

B. Monk, MD, FACOG, FACS

R. Morris, MD

P. Morris, MD, MSc, MRCPI

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Fourth Quarterly Activity)

Patients with osteoporosis typically follow regimens that include nonpharmacologic and pharmacologic therapies. In this last of four installments of Experts Responding to Your Questions: Video Q&A, Dr. Nancy Lane offers practical advice on how to monitor patients for response and adherence. In addition, she describes a monitoring strategy unique to denosumab, a targeted monoclonal antibody recently approved for the treatment of postmenopausal women with osteoporosis at high risk for fracture....more

N. Lane, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Third Quarterly Activity)

The status of treatment-related safety concerns, the significance of mechanism of action when choosing a bone-active agent, and the prospect of switching agents in patients with suboptimal response are just a few of the topics Dr. Paul Miller addresses in this installment of Experts Responding to Your Questions: Video Q&A.
...more

P. Miller, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Second Quarterly Activity)

In this second installment of Experts Responding to Your Questions: Video Q&A, join Dr. Paul Miller as he responds to your questions about risk factors for fracture and using bone mineral density to diagnose osteoporosis. ...more

P. Miller, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (First Quarterly Activity)

Do you have a clinical question you would like to ask an expert? In the first quarterly installment of Experts Responding to Your Questions: Video Q&A, Dr. Dolores Shoback answers questions from several practicing clinicians. They wanted to know about duration of therapy, the role of bone markers, safety and efficacy of new therapies, and more. Join Dr. Shoback as she shares her insights regarding these important clinical considerations. ...more

D. Shoback, MD

Menopause — Unraveling the Complexities of Menopause Management

Multidisciplinary clinical experts, led by co-chairs Richard J. Santen, MD, and Nanette F. Santoro, MD, help unravel the complexities of menopause management in this engaging multifaceted program.

This CME webcast, produced from a live symposium held during The Endocrine Society’s 90th Annual Meeting, is tailored to meet clinicians' specific educational needs and areas of interest....more

R. Santen, MD

N. Santoro, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Fourth Quarterly Activity)

N. Lane, MD

Ovarian Cancer — Personalizing Treatment and Managing Patient Concerns

Drs. Bradley Monk and Robert Coleman examine practical issues to consider in managing toxicities associated with antiangiogenic agents: dealing with side effects of first-line versus palliative treatment, the possibility of dose reduction to alleviate toxicities, risk factors for catastrophic side effects such as RPLS and GI perforation, and whether patients with serious side effects can be re-treated when these events have resolved. They also address the role of sensitivity tests and molecular profiling in determining treatment....more

B. Monk, MD, FACOG, FACS

Ovarian Cancer — Using Targeted Therapies in a Real-World Setting

In this engaging podcast, Drs. Bradley Monk and Robert Burger discuss important practical issues regarding the use of antiangiogenic therapy to treat epithelial ovarian cancer, including the possible value of targeted agents as maintenance therapy, the correct dosage and duration of targeted therapy, and the role of CA125 in determining tumor progression with a biologic agent....more

B. Monk, MD, FACOG, FACS

Osteoporosis — Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer

Agents targeting the vascular endothelial growth factor (VEGF) pathway have become standard therapies in the treatment of a wide variety of solid tumors. Several of these agents, such as bevacizumab, sorafenib, and sunitinib, are now being explored in the treatment of ovarian cancer. In addition, new agents directed against nonvascular targets involved in the pathophysiology of ovarian cancer have shown promise in preliminary trials. Join Dr. Bradley J. Monk as he leads a discussion with two other experts in the field, Dr. Robert Burger and Dr. Robert Coleman, as they evaluate the benefits and risks of these exciting drugs in the treatment of ovarian cancer....more

B. Monk, MD, FACOG, FACS

Ovarian Cancer — Controversies in Targeted Therapy: Management of Recurrent Ovarian Cancer—Practical Case-Based Discussions

B. Monk, MD, FACOG, FACS

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Third Quarterly Activity)

P. Miller, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (Second Quarterly Activity)

P. Miller, MD

Osteoporosis — Experts Responding to Your Questions: Video Q&A (First Quarterly Activity)

D. Shoback, MD

Breast Cancer — Personalizing Breast Cancer Management: Update on Targeted Therapies and Molecular Diagnostics

Listen as Drs. Harold J. Burstein and Ian E. Smith provide an update on targeted therapies and how to personalize their use in the treatment of breast cancer. The discussion focuses on how to optimize trastuzumab regimens, treatment of small HER2-positive lesions, other HER2 agents, PARP inhibitors, and antiangiogenesis inhibitors. Drs. Burstein and Smith also address the use of molecular diagnostic tools to identify patients likely to benefit from adjuvant chemotherapy....more

H. Burstein, MD, PhD

Osteoporosis — Expert Insight Into: Novel Therapy in Prevention of Fractures in Postmenopausal Women with Osteoporosis

Previous clinical trials have demonstrated that twice-yearly subcutaneous injections of the anti-RANKL antibody denosumab increase bone mineral density and reduce bone turnover. In this course, Dr. Ethel Siris discusses results from the multinational FREEDOM clinical trial, which assessed the effects of denosumab on fracture risk among postmenopausal women with osteoporosis....more

E. Siris, MD